7:["$","div",null,{"className":"","children":[["$","main",null,{"role":"main","className":"w-full text-white sr-only","children":[["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative z-10","children":[["$","div",null,{"id":"","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","header",null,{"className":"flex flex-col gap-4 pt-8 sm:pt-12","children":["$","div",null,{"className":"flex flex-col items-center gap-6","children":[["$","div",null,{"className":"relative","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1741172802.jpeg","alt":"Oxford Nanopore Technologies logo","width":120,"height":120,"className":"rounded-lg object-contain","priority":true}]}],["$","div",null,{"className":"text-center","children":[["$","h1",null,{"className":"text-2xl md:text-4xl lg:text-5xl font-bold text-white mb-4","children":["Oxford Nanopore Technologies",": ","Oxford Nanopore: Reading DNA Like Never Before"]}],["$","h2",null,{"className":"text-lg md:text-xl text-gray-300 max-w-3xl mx-auto","children":"Nvidia, Apple, Oracle and bioMerieux all believe in the story, so why shouldn't you?"}]]}],["$","div",null,{"className":"flex flex-col items-center gap-2 text-center","children":[["$","div",null,{"className":"flex items-center gap-2 text-sm text-gray-400","children":[["$","span",null,{"children":["LON",":"]}],["$","span",null,{"className":"font-medium text-white","children":"ONT"}]]}],["$","div",null,{"className":"flex items-center gap-3","children":[["$","span",null,{"className":"text-2xl font-bold text-white","children":"GBX118.33"}],["$","span",null,{"className":"text-sm font-medium text-red-400","children":"-2.04%"}]]}]]}],["$","div",null,{"className":"flex flex-wrap justify-center gap-4 text-sm text-gray-400","children":[["$","span",null,{"children":["Updated: ","May 02, 2025"]}],["$","div",null,{"className":"flex flex-wrap gap-2","children":[["$","span","76",{"className":"bg-gray-800 px-2 py-1 rounded","children":"Technology"}],["$","span","77",{"className":"bg-gray-800 px-2 py-1 rounded","children":"Healthcare"}]]}]]}],["$","div",null,{"className":"flex flex-wrap justify-center gap-2 text-xs","children":[["$","span",null,{"className":"bg-blue-900/30 text-blue-300 px-2 py-1 rounded","children":"medium"}],["$","span",null,{"className":"bg-green-900/30 text-green-300 px-2 py-1 rounded","children":"uk"}]]}]]}]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative ","children":[["$","div",null,{"id":"","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"id":"bull-bear-case","aria-label":"Bull & Bear Case","children":[["$","header",null,{"className":"text-center mb-12","children":[["$","h2",null,{"className":"text-2xl md:text-3xl font-semibold text-white mb-4","children":"Bull & Bear Case"}],["$","p",null,{"className":"text-gray-300 max-w-2xl mx-auto","children":"An overview of the main reasons to invest and the key risks involved."}]]}],["$","div",null,{"className":"flex gap-8 flex-col xl:flex-row","children":[["$","div",null,{"className":"flex-1","children":["$","div",null,{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-6","children":["$","h3",null,{"className":"text-lg font-medium text-white mb-2 pb-2 border-b border-[#3F3D42]","children":"Bull Case"}]}],["$","div",null,{"className":"space-y-4","children":[["$","article","0",{"className":"flex gap-3 items-start py-2","children":[["$","div",null,{"className":"mt-1 flex-shrink-0","children":["$","div",null,{"className":"w-4 h-4 rounded-full bg-green-800 flex items-center justify-center","children":["$","svg",null,{"width":"12","height":"12","viewBox":"0 0 16 16","fill":"none","xmlns":"http://www.w3.org/2000/svg","children":["$","path",null,{"stroke":"#D9D7DB","strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":"1.5","d":"M12.444 5.778 8.947 9.275c-.176.176-.264.264-.366.297a.444.444 0 0 1-.274 0c-.102-.032-.19-.12-.366-.297L6.725 8.06c-.176-.176-.264-.264-.366-.297a.444.444 0 0 0-.274 0c-.102.033-.19.12-.366.297l-2.164 2.164m8.89-4.445H9.332m3.111 0V8.89"}]}]}]}],["$","div",null,{"className":"flex-1","children":[["$","h4",null,{"className":"font-medium text-sm text-white mb-1","children":"Expanding Clinical & Biopharma Adoption"}],["$","p",null,{"className":"text-xs text-[#BAB9BD]","children":"ONT is rapidly growing in clinical genomics, with large-scale contracts supporting long-term revenue expansion."}]]}]]}],["$","article","1",{"className":"flex gap-3 items-start py-2","children":[["$","div",null,{"className":"mt-1 flex-shrink-0","children":["$","div",null,{"className":"w-4 h-4 rounded-full bg-green-800 flex items-center justify-center","children":["$","svg",null,{"width":"12","height":"12","viewBox":"0 0 16 16","fill":"none","xmlns":"http://www.w3.org/2000/svg","children":["$","path",null,{"stroke":"#D9D7DB","strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":"1.5","d":"M12.444 5.778 8.947 9.275c-.176.176-.264.264-.366.297a.444.444 0 0 1-.274 0c-.102-.032-.19-.12-.366-.297L6.725 8.06c-.176-.176-.264-.264-.366-.297a.444.444 0 0 0-.274 0c-.102.033-.19.12-.366.297l-2.164 2.164m8.89-4.445H9.332m3.111 0V8.89"}]}]}]}],["$","div",null,{"className":"flex-1","children":[["$","h4",null,{"className":"font-medium text-sm text-white mb-1","children":"Technology Leadership"}],["$","p",null,{"className":"text-xs text-[#BAB9BD]","children":"Oxford Nanopore is the only company globally producing handheld, portable sequencing devices for real-time, in-field DNA/RNA analysis, —that sets it apart in next-generation genomic analysis."}]]}]]}],["$","article","2",{"className":"flex gap-3 items-start py-2","children":[["$","div",null,{"className":"mt-1 flex-shrink-0","children":["$","div",null,{"className":"w-4 h-4 rounded-full bg-green-800 flex items-center justify-center","children":["$","svg",null,{"width":"12","height":"12","viewBox":"0 0 16 16","fill":"none","xmlns":"http://www.w3.org/2000/svg","children":["$","path",null,{"stroke":"#D9D7DB","strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":"1.5","d":"M12.444 5.778 8.947 9.275c-.176.176-.264.264-.366.297a.444.444 0 0 1-.274 0c-.102-.032-.19-.12-.366-.297L6.725 8.06c-.176-.176-.264-.264-.366-.297a.444.444 0 0 0-.274 0c-.102.033-.19.12-.366.297l-2.164 2.164m8.89-4.445H9.332m3.111 0V8.89"}]}]}]}],["$","div",null,{"className":"flex-1","children":[["$","h4",null,{"className":"font-medium text-sm text-white mb-1","children":"Broad Global Applicability"}],["$","p",null,{"className":"text-xs text-[#BAB9BD]","children":"ONT devices are deployed across multiple sectors spanning healthcare, agriculture, environmental science, and academic research, enhancing ONT’s market resilience and expanding its TAM."}]]}]]}]]}]]}]}]}],["$","div",null,{"className":"flex-1","children":["$","div",null,{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-6","children":["$","h3",null,{"className":"text-lg font-medium text-white mb-2 pb-2 border-b border-[#3F3D42]","children":"Bear Case"}]}],["$","div",null,{"className":"space-y-4","children":[["$","article","0",{"className":"flex gap-3 items-start py-2","children":[["$","div",null,{"className":"mt-1 flex-shrink-0","children":["$","div",null,{"className":"w-4 h-4 rounded-full bg-red-800 flex items-center justify-center","children":["$","svg",null,{"width":"12","height":"12","viewBox":"0 0 16 16","fill":"none","xmlns":"http://www.w3.org/2000/svg","children":["$","path",null,{"stroke":"#D9D7DB","strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":"1.5","d":"M12.444 10.223 8.947 6.726c-.176-.176-.264-.264-.366-.297a.445.445 0 0 0-.274 0c-.102.033-.19.12-.366.297L6.725 7.942c-.176.176-.264.264-.366.297a.444.444 0 0 1-.274 0c-.102-.033-.19-.12-.366-.297L3.555 5.778m8.89 4.445H9.332m3.111 0V7.112"}]}]}]}],["$","div",null,{"className":"flex-1","children":[["$","h4",null,{"className":"font-medium text-sm text-white mb-1","children":"Competition from Established Players"}],["$","p",null,{"className":"text-xs text-[#BAB9BD]","children":"Illumina and PacBio remain formidable competitors, leveraging existing market share and technology advancements."}]]}]]}],["$","article","1",{"className":"flex gap-3 items-start py-2","children":[["$","div",null,{"className":"mt-1 flex-shrink-0","children":["$","div",null,{"className":"w-4 h-4 rounded-full bg-red-800 flex items-center justify-center","children":["$","svg",null,{"width":"12","height":"12","viewBox":"0 0 16 16","fill":"none","xmlns":"http://www.w3.org/2000/svg","children":["$","path",null,{"stroke":"#D9D7DB","strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":"1.5","d":"M12.444 10.223 8.947 6.726c-.176-.176-.264-.264-.366-.297a.445.445 0 0 0-.274 0c-.102.033-.19.12-.366.297L6.725 7.942c-.176.176-.264.264-.366.297a.444.444 0 0 1-.274 0c-.102-.033-.19-.12-.366-.297L3.555 5.778m8.89 4.445H9.332m3.111 0V7.112"}]}]}]}],["$","div",null,{"className":"flex-1","children":[["$","h4",null,{"className":"font-medium text-sm text-white mb-1","children":"Profitability Concerns"}],["$","p",null,{"className":"text-xs text-[#BAB9BD]","children":"ONT has yet to achieve consistent profitability, with high R&D and expansion costs potentially delaying EBITDA breakeven."}]]}]]}],["$","article","2",{"className":"flex gap-3 items-start py-2","children":[["$","div",null,{"className":"mt-1 flex-shrink-0","children":["$","div",null,{"className":"w-4 h-4 rounded-full bg-red-800 flex items-center justify-center","children":["$","svg",null,{"width":"12","height":"12","viewBox":"0 0 16 16","fill":"none","xmlns":"http://www.w3.org/2000/svg","children":["$","path",null,{"stroke":"#D9D7DB","strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":"1.5","d":"M12.444 10.223 8.947 6.726c-.176-.176-.264-.264-.366-.297a.445.445 0 0 0-.274 0c-.102.033-.19.12-.366.297L6.725 7.942c-.176.176-.264.264-.366.297a.444.444 0 0 1-.274 0c-.102-.033-.19-.12-.366-.297L3.555 5.778m8.89 4.445H9.332m3.111 0V7.112"}]}]}]}],["$","div",null,{"className":"flex-1","children":[["$","h4",null,{"className":"font-medium text-sm text-white mb-1","children":"Execution Risk in Clinical Expansion"}],["$","p",null,{"className":"text-xs text-[#BAB9BD]","children":"The transition from research to clinical applications presents regulatory and adoption challenges that may slow market penetration."}]]}]]}]]}]]}]}]}]]}]]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative ","children":[["$","div",null,{"id":"","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"id":"executive-summary","aria-label":"Executive Summary","children":[["$","header",null,{"children":["$","h2",null,{"className":"text-xl text-white font-semibold md:text-4xl flex-1 text-center mb-10","children":"Executive Summary"}]}],["$","div",null,{"className":"flex gap-8 flex-col-reverse md:flex-row justify-center","children":[["$","article",null,{"className":"w-full md:w-[584px] flex flex-col items-start","children":[["$","h3",null,{"className":"md:text-lg font-medium text-white mb-4 text-center","children":"Decoding tomorrow"}],["$","div",null,{"className":" m-0 text-[#D9D7DB] prose prose-invert max-w-none","dangerouslySetInnerHTML":{"__html":"$19"}}],["$","div",null,{"className":"mt-10","children":["$","a",null,{"href":"https://app.curationconnect.com/account/signup","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center px-6 py-3 bg-blue-600 hover:bg-blue-700 text-white font-medium rounded-lg transition-colors duration-200","aria-label":"Visit +Watchlist - opens in new tab","children":"+Watchlist"}]}]]}],["$","div",null,{"className":"w-full md:w-6/12","children":["$","div",null,{"className":"relative w-full aspect-video lg:w-[560px]","children":["$","iframe",null,{"src":"https://player.vimeo.com/video/957043286?share=copy","title":"Oxford Nanopore CEO Interview","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy","style":{"borderRadius":"4px","overflow":"hidden"}}]}]}]]}]]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative ","children":[["$","div",null,{"id":"investment-thesis","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"aria-label":"Investment Thesis","children":[["$","header",null,{"className":"text-center mb-12","children":[["$","h2",null,{"className":"text-2xl md:text-3xl font-semibold text-white mb-4","children":"Investment Thesis"}],["$","p",null,{"className":"text-gray-300 max-w-2xl mx-auto","children":"Overview of buy and sell case of the business."}]]}],["$","div",null,{"className":"space-y-16","children":[["$","div",null,{"className":"flex flex-col xl:flex-row gap-8","children":[["$","div",null,{"className":"lg:w-[378px] pt-4","children":[["$","h3",null,{"className":"text-xl font-medium text-white mb-2","children":"Why Invest?"}],["$","p",null,{"className":"text-[#D9D7DB]","children":"Key pieces of information about the business that you need to know about."}]]}],["$","div",null,{"className":"flex-1","children":["$","div",null,{"className":"grid gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4","children":["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Market Expansion into Clinical & Biopharma"}]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

ONT’s sequencing technology is gaining traction in clinical and applied genomics, moving beyond research-focused applications. The company reported 40% growth in applied genomics revenue, with biopharma and clinical applications contributing significantly. Large-scale contracts such as PRECISE Singapore and Genomics England are reinforcing ONT’s presence in high-value sequencing markets.

"}}]]}],["$","article","1",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4","children":["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Long-read gene sequencing"}]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

ONT revolutionizes sequencing with its real-time, long-read technology, overcoming the limitations of traditional methods that are often slow and require extensive post-processing. It's highly portable and flexible devices enable sequencing in diverse environments beyond conventional laboratories, allowing for immediate analysis as the sequencing occurs. This portability is particularly advantageous for fieldwork, environmental studies, and even space research, as demonstrated by the use of the MinION on the International Space Station!

"}}]]}],["$","article","2",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4","children":["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Partnerships"}]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

ONT has formed key collaborations with Oracle, Tencent, NVidia, Apple, Lonza, Biomerieux, 10x Genomics, Mayo Clinic and many more. This shows the faith that world-class companies have in Oxford Nanopore Technologies' work.

"}}]]}]]}]}]]}],["$","div",null,{"className":"flex flex-col xl:flex-row gap-8","children":[["$","div",null,{"className":"lg:w-[378px] pt-4","children":[["$","h3",null,{"className":"text-xl font-medium text-white mb-2","children":"Catalysts"}],["$","p",null,{"className":"text-[#D9D7DB]","children":"The key events that could drive investment opportunities and shift markets."}]]}],["$","div",null,{"className":"flex-1","children":["$","div",null,{"className":"grid gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4 flex items-center gap-3","children":[["$","span",null,{"className":"px-3 py-1 rounded-full text-xs font-medium bg-green-900/30 text-green-300","children":"Near term"}],"$undefined"]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

Drug-Resistant TB Profiling Partnership with bioMérieux

ONT’s partnership with bioMérieux to launch a drug-resistant TB profiling workflow in early 2025 is a key catalyst. With TB a major global health threat, especially in low- and middle-income countries, this collaboration positions ONT at the forefront of diagnostics.

Expansion into Biopharma Markets

ONT plans to expand into direct RNA sequencing for biopharma applications. Its inaugural Biopharma Day in September 2024 highlighted growing industry adoption, reinforcing its role in drug discovery, clinical trials, and manufacturing. With a focus on end-to-end workflows and regulatory approvals for PromethION and GridION, ONT is well-positioned for continued growth in the biopharma market.

"}}]]}],["$","article","1",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4 flex items-center gap-3","children":[["$","span",null,{"className":"px-3 py-1 rounded-full text-xs font-medium bg-yellow-900/30 text-yellow-300","children":"Medium term"}],"$undefined"]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

Progress Towards Cash Flow Positive

The company expects sustained >30% revenue growth through 2027. Larger-scale contracts, increased flow cell utilization, and growing demand for real-time, portable sequencing solutions will drive further adoption. The company’s substantial cash position, with over £400 million in cash and cash equivalents, supports its continued innovation and capacity to meet medium-term margin targets.

Cutting-Edge Technology & Innovation Pipeline

ONT is advancing into protein sequencing, potentially unlocking a new multi-billion-dollar market in the coming years.

"}}]]}],["$","article","2",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4 flex items-center gap-3","children":[["$","span",null,{"className":"px-3 py-1 rounded-full text-xs font-medium bg-blue-900/30 text-blue-300","children":"Long term"}],"$undefined"]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"$1a"}}]]}]]}]}]]}],["$","div",null,{"className":"flex flex-col xl:flex-row gap-8","children":[["$","div",null,{"className":"lg:w-[378px] pt-4","children":[["$","h3",null,{"className":"text-xl font-medium text-white mb-2","children":"Key Risks"}],["$","p",null,{"className":"text-[#D9D7DB]","children":"Key pieces of information about the business risks that you need to know about."}]]}],["$","div",null,{"className":"flex-1","children":["$","div",null,{"className":"grid gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4","children":["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Competitive Pressures"}]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

While ONT leads in long-read sequencing, competition from Illumina’s short-read platforms and PacBio’s optical sequencing could limit market share expansion. Competitor advancements in accuracy and cost efficiency may challenge ONT’s growth trajectory.

"}}]]}],["$","article","1",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4","children":["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Profitability & Cash Flow Management"}]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

Despite strong revenue growth, ONT has not yet reached profitability. With a targeted EBITDA breakeven by 2027, managing operational expenses and maintaining R&D investment without impacting margins remains a key challenge.

"}}]]}],["$","article","2",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4","children":["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Regulatory & Market Adoption Challenges"}]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

Expanding into clinical and applied genomics requires regulatory approvals and widespread industry acceptance. Delays in product approvals, adoption rates, or reimbursement structures could impact ONT’s clinical revenue growth.

"}}]]}]]}]}]]}]]}]]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative ","children":[["$","div",null,{"id":"experts","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"aria-label":"Experts","children":[["$","header",null,{"className":"text-center mb-12","children":[["$","h2",null,{"className":"text-2xl md:text-3xl font-semibold text-white mb-4","children":"Follow the Experts"}],["$","p",null,{"className":"text-gray-300 max-w-2xl mx-auto","children":"Quickly navigate key insights from industry experts and leverage their knowledge and market intelligence. "}]]}],["$","div",null,{"className":"space-y-12","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"flex flex-col md:flex-row gap-6 mb-6","children":[["$","div",null,{"className":"flex-shrink-0","children":["$","div",null,{"className":"relative w-24 h-24 md:w-32 md:h-32 mx-auto md:mx-0","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1722953638.jpeg","alt":"Andrew Gao profile","fill":true,"className":"rounded-full object-cover","sizes":"(max-width: 768px) 96px, 128px"}]}]}],["$","div",null,{"className":"flex-1 text-center md:text-left","children":[["$","h3",null,{"className":"text-xl md:text-2xl font-semibold text-white mb-2","children":"Andrew Gao"}],["$","p",null,{"className":"text-blue-400 font-medium mb-2","children":"Science and venture commentator"}],["$","p",null,{"className":"text-gray-300 text-sm","children":["35.8k"," audience"]}],["$","div",null,{"className":"flex justify-center md:justify-start gap-4 mt-4","children":[["$","a",null,{"href":"https://x.com/itsandrewgao","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Andrew Gao's X profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M18.244 2.25h3.308l-7.227 8.26 8.502 11.24H16.17l-5.214-6.817L4.99 21.75H1.68l7.73-8.835L1.254 2.25H8.08l4.713 6.231zm-1.161 17.52h1.833L7.084 4.126H5.117z"}]}]}],["$","a",null,{"href":"https://www.linkedin.com/in/andrewgao22/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Andrew Gao's LinkedIn profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}]}],["$","a",null,{"href":"https://andrewgao.dev/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"Visit Andrew Gao's website - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M21 12a9 9 0 01-9 9m9-9a9 9 0 00-9-9m9 9H3m9 9v-9m0-9v9m0 9c-5 0-9-4-9-9s4-9 9-9"}]}]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-4","children":"Expert Insights"}],["$","div",null,{"className":"grid gap-4","children":[["$","div","0",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"x"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"“It cost $3billion to sequence the first human genome… Oxford Nanopore is developing a tiny DNA sequencer that plugs into your iPhone, and might cost ~$1,000”"}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://x.com/itsandrewgao/status/1794488206995636230","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"See more - opens in new tab","children":["See more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]]}]]}]]}]}],["$","article","1",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"flex flex-col md:flex-row gap-6 mb-6","children":[["$","div",null,{"className":"flex-shrink-0","children":["$","div",null,{"className":"relative w-24 h-24 md:w-32 md:h-32 mx-auto md:mx-0","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1722956500.jpeg","alt":"Greg Smith profile","fill":true,"className":"rounded-full object-cover","sizes":"(max-width: 768px) 96px, 128px"}]}]}],["$","div",null,{"className":"flex-1 text-center md:text-left","children":[["$","h3",null,{"className":"text-xl md:text-2xl font-semibold text-white mb-2","children":"Greg Smith"}],["$","p",null,{"className":"text-blue-400 font-medium mb-2","children":"CEO at IP Group"}],["$","p",null,{"className":"text-gray-300 text-sm","children":["1k"," audience"]}],["$","div",null,{"className":"flex justify-center md:justify-start gap-4 mt-4","children":[["$","a",null,{"href":"https://x.com/FierceBiotech","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Greg Smith's X profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M18.244 2.25h3.308l-7.227 8.26 8.502 11.24H16.17l-5.214-6.817L4.99 21.75H1.68l7.73-8.835L1.254 2.25H8.08l4.713 6.231zm-1.161 17.52h1.833L7.084 4.126H5.117z"}]}]}],["$","a",null,{"href":"https://www.linkedin.com/in/greg-smith-5a99b9/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Greg Smith's LinkedIn profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}]}],["$","a",null,{"href":"https://www.fiercebiotech.com/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"Visit Greg Smith's website - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M21 12a9 9 0 01-9 9m9-9a9 9 0 00-9-9m9 9H3m9 9v-9m0-9v9m0 9c-5 0-9-4-9-9s4-9 9-9"}]}]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-4","children":"Expert Insights"}],["$","div",null,{"className":"grid gap-4","children":[["$","div","0",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"linkedin"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"“[Long read gene sequencing has] the power to change lives, reducing what can be a lifetime of genetic tests to weeks or days with the richer data that ONT enables.”"}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://www.linkedin.com/feed/update/urn:li:activity:7201191054258110464/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"See more - opens in new tab","children":["See more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}],["$","div","1",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"linkedin"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"“Gordon Sanghera, set out the many commercial partnerships through which ONT is seeking to unlock high potential applied sequencing markets.”"}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://www.linkedin.com/feed/update/urn:li:activity:7201191054258110464/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"See more - opens in new tab","children":["See more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}],["$","div","2",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"linkedin"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"“Longer term, the real prize is in the ‘applied markets’ so it was great to see an overview of the pathway for their products through to future, regulated in-vitro diagnostics.”"}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://www.linkedin.com/feed/update/urn:li:activity:7201191054258110464/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"See more - opens in new tab","children":["See more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}],["$","div","3",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"linkedin"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"“[Infectious disease] is an area where nanopore-based sequencing is mature as well as giving the market advantages of speed and suitability for any setting.”"}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://www.linkedin.com/feed/update/urn:li:activity:7201191054258110464/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"See more - opens in new tab","children":["See more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]]}]]}]]}]}],["$","article","2",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"flex flex-col md:flex-row gap-6 mb-6","children":[["$","div",null,{"className":"flex-shrink-0","children":["$","div",null,{"className":"relative w-24 h-24 md:w-32 md:h-32 mx-auto md:mx-0","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1740665242.jpeg","alt":"Dr Rebecca Tarvin profile","fill":true,"className":"rounded-full object-cover","sizes":"(max-width: 768px) 96px, 128px"}]}]}],["$","div",null,{"className":"flex-1 text-center md:text-left","children":[["$","h3",null,{"className":"text-xl md:text-2xl font-semibold text-white mb-2","children":"Dr Rebecca Tarvin"}],["$","p",null,{"className":"text-blue-400 font-medium mb-2","children":"Assistant Professor at University of California, Berkeley"}],["$","p",null,{"className":"text-gray-300 text-sm","children":["5k"," audience"]}],["$","div",null,{"className":"flex justify-center md:justify-start gap-4 mt-4","children":[["$","a",null,{"href":"https://x.com/frogsicles","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Dr Rebecca Tarvin's X profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M18.244 2.25h3.308l-7.227 8.26 8.502 11.24H16.17l-5.214-6.817L4.99 21.75H1.68l7.73-8.835L1.254 2.25H8.08l4.713 6.231zm-1.161 17.52h1.833L7.084 4.126H5.117z"}]}]}],["$","a",null,{"href":"https://www.linkedin.com/in/rebecca-tarvin-0b9a801b/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Dr Rebecca Tarvin's LinkedIn profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}]}],["$","a",null,{"href":"https://ib.berkeley.edu/people/faculty/tarvinr","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"Visit Dr Rebecca Tarvin's website - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M21 12a9 9 0 01-9 9m9-9a9 9 0 00-9-9m9 9H3m9 9v-9m0-9v9m0 9c-5 0-9-4-9-9s4-9 9-9"}]}]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-4","children":"Expert Insights"}],["$","div",null,{"className":"grid gap-4","children":[["$","div","0",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"x"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"\"In particular, the cost to sequence ...1kb...with Sanger sequencing abroad is ∼$20 USD. In contrast, the cost to sequence a gene with an Oxford Nanopore Technologies instrument locally is only ∼$1.73 USD.\" awesome impact”"}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://x.com/frogsicles/status/1891994451394036127","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read Here - opens in new tab","children":["Read Here",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]]}]]}]]}]}],["$","article","3",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"flex flex-col md:flex-row gap-6 mb-6","children":[["$","div",null,{"className":"flex-shrink-0","children":["$","div",null,{"className":"relative w-24 h-24 md:w-32 md:h-32 mx-auto md:mx-0","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1740666043.jpeg","alt":"Aponia Analytics profile","fill":true,"className":"rounded-full object-cover","sizes":"(max-width: 768px) 96px, 128px"}]}]}],["$","div",null,{"className":"flex-1 text-center md:text-left","children":[["$","h3",null,{"className":"text-xl md:text-2xl font-semibold text-white mb-2","children":"Aponia Analytics"}],["$","p",null,{"className":"text-blue-400 font-medium mb-2","children":"global health intelligence"}],["$","p",null,{"className":"text-gray-300 text-sm","children":["4k"," audience"]}],["$","div",null,{"className":"flex justify-center md:justify-start gap-4 mt-4","children":[["$","a",null,{"href":"https://x.com/AponiaAnalytics","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Aponia Analytics's X profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M18.244 2.25h3.308l-7.227 8.26 8.502 11.24H16.17l-5.214-6.817L4.99 21.75H1.68l7.73-8.835L1.254 2.25H8.08l4.713 6.231zm-1.161 17.52h1.833L7.084 4.126H5.117z"}]}]}],["$","a",null,{"href":"https://www.linkedin.com/company/aponia-analytics/posts/?feedView=all","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Aponia Analytics's LinkedIn profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}]}],["$","a",null,{"href":"https://aponiaholding.com/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"Visit Aponia Analytics's website - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M21 12a9 9 0 01-9 9m9-9a9 9 0 00-9-9m9 9H3m9 9v-9m0-9v9m0 9c-5 0-9-4-9-9s4-9 9-9"}]}]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-4","children":"Expert Insights"}],["$","div",null,{"className":"grid gap-4","children":[["$","div","0",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"x"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"“Oxford Nanopore’s sequencing will improve disease detection in cancer, rare diseases, and infections.”"}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://x.com/AponiaAnalytics/status/1889371261320548798","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read Here - opens in new tab","children":["Read Here",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]]}]]}]]}]}]]}]]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative ","children":[["$","div",null,{"id":"investor-materials","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"aria-label":"Investor Materials","children":[["$","header",null,{"className":"text-center mb-12","children":[["$","h2",null,{"className":"text-2xl md:text-3xl font-semibold text-white mb-4","children":"Investor Materials"}],["$","p",null,{"className":"text-gray-300 max-w-2xl mx-auto","children":"Access the most recent investor updates published by the company."}]]}],["$","div",null,{"className":"space-y-16","children":[["$","div","0",{"className":"space-y-8","children":[["$","div",null,{"className":"text-center","children":["$","h3",null,{"className":"text-xl font-medium text-white mb-4","children":"Key Investor Materials"}]}],["$","div",null,{"className":"grid gap-6","children":[["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 gap-6","children":[["$","div","0",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/nwnGx2i42m8?start=undefined","title":"hi","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}]]}],["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"42nd Annual J.P Morgan Healthcare Conference"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-red-900/30 text-red-300","children":"PDF"}]]}],null,["$","footer",null,{"children":["$","a",null,{"href":"https://a.storyblok.com/f/196663/x/7ba1f5a928/ont-jpm-final-presentation-9jan2024.pdf","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View PDF: 42nd Annual J.P Morgan Healthcare Conference - opens in new tab","children":["View PDF",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}],["$","article","1",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Single-cell transcriptomics with Oxford Nanopore"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-blue-900/30 text-blue-300","children":"Article"}]]}],["$","p",null,{"className":"text-gray-300 text-sm mb-4 line-clamp-3","children":"This guide introduces the single-cell RNA nanopore sequencing workflow, for ultra-rich data without compromise."}],["$","footer",null,{"children":["$","a",null,{"href":"https://nanoporetech.com/resource-centre/getting-started-guide-single-cell-transcriptomics","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read article: Single-cell transcriptomics with Oxford Nanopore - opens in new tab","children":["Read Article",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}],["$","article","2",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"2024 Interim Results"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-red-900/30 text-red-300","children":"PDF"}]]}],null,["$","footer",null,{"children":["$","a",null,{"href":"https://a.storyblok.com/f/196663/x/f265e0a793/ont-2024-interim-results-presentation-slides-3-sep-2024-final.pdf","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View PDF: 2024 Interim Results - opens in new tab","children":["View PDF",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}]]}]]}]]}],["$","div","1",{"className":"space-y-8","children":[["$","div",null,{"className":"text-center","children":["$","h3",null,{"className":"text-xl font-medium text-white mb-4","children":"Gene Sequencing"}]}],["$","div",null,{"className":"grid gap-6","children":[["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 gap-6","children":[["$","div","0",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/E0z4waO35QI","title":"How sequencing works","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}]]}],["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Oxford Nanopore announces breakthrough technology performance to deliver complete human genome assemblies and richer multiomic data in London Calling"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-blue-900/30 text-blue-300","children":"Article"}]]}],["$","p",null,{"className":"text-gray-300 text-sm mb-4 line-clamp-3","children":"Oxford Nanopore Chief Technology, Innovation and Product Officer Clive G Brown announced breakthrough performance data and new platform updates in his technology update at the company’s annual London Calling conference, held between 21 and 24 May 2024."}],["$","footer",null,{"children":["$","a",null,{"href":"https://nanoporetech.com/news/oxford-nanopore-announces-breakthrough-technology-performance-to-deliver-complete-human-genomes-and-richer-multiomic-data-in-london-calling-tech-update","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read article: Oxford Nanopore announces breakthrough technology performance to deliver complete human genome assemblies and richer multiomic data in London Calling - opens in new tab","children":["Read Article",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}],["$","article","1",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Sustainability Report"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-red-900/30 text-red-300","children":"PDF"}]]}],null,["$","footer",null,{"children":["$","a",null,{"href":"https://a.storyblok.com/f/196663/x/947e918766/fy_23_sustainability_report-v2.pdf","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View PDF: Sustainability Report - opens in new tab","children":["View PDF",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}],["$","article","2",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Nanopore sequencing solutions for cell and gene therapies"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-red-900/30 text-red-300","children":"PDF"}]]}],null,["$","footer",null,{"children":["$","a",null,{"href":"https://a.storyblok.com/f/196663/78c2e3cc25/biopharma-cgt-brochure-br_1220-en-_v1_15jan2024.pdf","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View PDF: Nanopore sequencing solutions for cell and gene therapies - opens in new tab","children":["View PDF",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}]]}]]}]]}]]}]]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative ","children":[["$","div",null,{"id":"external-insights","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"aria-label":"External Insights","children":[["$","header",null,{"className":"text-center mb-12","children":[["$","h2",null,{"className":"text-2xl md:text-3xl font-semibold text-white mb-4","children":"External Insights"}],["$","p",null,{"className":"text-gray-300 max-w-2xl mx-auto","children":"A curated collection of third-party content relevant to the company and sector to help inform your investment decision."}]]}],["$","div",null,{"className":"space-y-16","children":[["$","div","0",{"className":"space-y-8","children":[["$","div",null,{"className":"text-center","children":["$","h3",null,{"className":"text-xl font-medium text-white mb-4","children":"Partnerships"}]}],["$","div",null,{"className":"grid gap-6","children":[["$","div",null,{"className":"grid grid-cols-1 lg:grid-cols-2 gap-6","children":[[["$","div","0",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/UNZcwGNYiGY","title":"ONT x Nvidia 1","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}],["$","div","1",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/dnKJTaYoAh8","title":"ONT x Nvidia 2","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}]],[["$","div","0",{"className":"aspect-video lg:aspect-auto lg:h-[352px]","children":["$","iframe",null,{"src":"https://open.spotify.com/embed/episode/2AlvvggQsgAdskpiacdqSO?si=aVE9eHhfScSnohKztIugJA","title":"Gordon Sanghera, Co-Founder and CEO","className":"w-full h-full rounded-lg","frameBorder":"0","allow":"autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture","loading":"lazy"}]}]]]}],["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Mayo Clinic and Oxford Nanopore announce collaboration to advance precision medicine for cancer and genetic disorders"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-green-900/30 text-green-300","children":"Article"}]]}],null,["$","footer",null,{"children":["$","a",null,{"href":"https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-and-oxford-nanopore-announce-collaboration-to-advance-precision-medicine-for-cancer-and-genetic-disorders/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read article: Mayo Clinic and Oxford Nanopore announce collaboration to advance precision medicine for cancer and genetic disorders - opens in new tab","children":["Read Article",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}]]}]]}]]}],["$","div","1",{"className":"space-y-8","children":[["$","div",null,{"className":"text-center","children":["$","h3",null,{"className":"text-xl font-medium text-white mb-4","children":"Academic Research"}]}],["$","div",null,{"className":"grid gap-6","children":[["$","div",null,{"className":"grid grid-cols-1 lg:grid-cols-2 gap-6","children":[[["$","div","0",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/FZeqKRtfKFU","title":"MinIOn","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}],["$","div","1",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/4iqTVa5-ePQ","title":"Cancer Genomics Consortium","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}]],[["$","div","0",{"className":"aspect-video lg:aspect-auto lg:h-[352px]","children":["$","iframe",null,{"src":"https://open.spotify.com/embed/episode/1H7SOKRg4DTbDxUXQB7e1f?si=fI3_sBK8TwGEKATDeC3dfg","title":"Long read sequencing","className":"w-full h-full rounded-lg","frameBorder":"0","allow":"autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture","loading":"lazy"}]}]]]}],["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Oxford Nanopore Technologies: a revolution in DNA and RNA sequencing technology"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-green-900/30 text-green-300","children":"Article"}]]}],["$","p",null,{"className":"text-gray-300 text-sm mb-4 line-clamp-3","children":"Only 20 years ago DNA sequencing was expensive, time-consuming and required specialised lab equipment. Oxford Nanopore Technologies’ low-cost, fast, portable, nanopore-based direct sequencing technology is opening up a wide range of new applications that would not have been possible in the early 2000s."}],["$","footer",null,{"children":["$","a",null,{"href":"https://www.mpls.ox.ac.uk/research/impact-case-studies/oxford-nanopore-technologies","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read article: Oxford Nanopore Technologies: a revolution in DNA and RNA sequencing technology - opens in new tab","children":["Read Article",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}]]}]]}]]}],["$","div","2",{"className":"space-y-8","children":[["$","div",null,{"className":"text-center","children":["$","h3",null,{"className":"text-xl font-medium text-white mb-4","children":"Use Cases"}]}],["$","div",null,{"className":"grid gap-6","children":[["$","div",null,{"className":"grid grid-cols-1 lg:grid-cols-2 gap-6","children":[[["$","div","0",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/J9IdgL0lMOg","title":"LSE webinar","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}],["$","div","1",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/-pwXXzu17JQ","title":"World's smallest gene sequencer","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}]],[["$","div","0",{"className":"aspect-video lg:aspect-auto lg:h-[352px]","children":["$","iframe",null,{"src":"https://open.spotify.com/embed/episode/2LfpMGldVuJEj2gWXe1Zlf?si=r96JPM9aSDuqjADT2RPgyQ","title":"ONT and Gordon Sanghera","className":"w-full h-full rounded-lg","frameBorder":"0","allow":"autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture","loading":"lazy"}]}]]]}],["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Nanopore sequencing technology, Bioinformatics and applications"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-green-900/30 text-green-300","children":"Article"}]]}],["$","p",null,{"className":"text-gray-300 text-sm mb-4 line-clamp-3","children":"Au and colleagues outline the field of nanopore sequencing."}],["$","footer",null,{"children":["$","a",null,{"href":"https://www.nature.com/articles/s41587-021-01108-x","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read article: Nanopore sequencing technology, Bioinformatics and applications - opens in new tab","children":["Read Article",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}]]}]]}]]}]]}]]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative ","children":[["$","div",null,{"id":"articles","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"aria-label":"Key Articles","children":[["$","header",null,{"className":"text-left mb-8","children":["$","h2",null,{"className":"text-2xl md:text-3xl font-semibold text-white","children":"Research"}]}],["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6 w-full","children":[["$","article","2733",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-all duration-200","children":["$undefined",["$","div",null,{"className":"p-4","children":[["$","header",null,{"className":"mb-3","children":[["$","h3",null,{"className":"text-lg font-medium text-white mb-2 line-clamp-2","children":null}],["$","div",null,{"className":"flex items-center gap-2 text-xs text-gray-400","children":["$undefined","$undefined","$undefined"]}]]}],null,["$","footer",null,{"children":["$","a",null,{"href":"https://6021764.fs1.hubspotusercontent-na1.net/hubfs/6021764/ONT%20Research%20note%20-%20Curation%20Collective.pdf","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read full article: null - opens in new tab","children":["Read Full Article",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]]}]]}]]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative ","children":[["$","div",null,{"id":"team","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"aria-label":"Team Members","children":[["$","header",null,{"className":"text-center mb-12","children":[["$","h2",null,{"className":"text-2xl md:text-3xl font-semibold text-white mb-4","children":"Team"}],["$","p",null,{"className":"text-gray-300 max-w-2xl mx-auto","children":"Meet the experienced professionals leading our organization"}]]}],["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-8","children":[["$","article","3636",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200 text-center","children":[["$","div",null,{"className":"relative w-full h-64 bg-gray-800","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1718270988.jpeg","alt":"Clive Brown - undefined","fill":true,"className":"object-cover","sizes":"(max-width: 768px) 100vw, (max-width: 1200px) 50vw, 33vw"}]}],["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h3",null,{"className":"text-xl font-semibold text-white mb-1","children":"Clive Brown"}],["$","p",null,{"className":"text-blue-400 font-medium","children":"$undefined"}]]}],"$undefined",["$","footer",null,{"children":["$","a",null,{"href":"https://www.linkedin.com/in/clive-brown-58507a178/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View Clive Brown's LinkedIn profile - opens in new tab","children":[["$","svg",null,{"className":"w-4 h-4 mr-2","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}],"LinkedIn Profile"]}]}]]}]]}],["$","article","3637",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200 text-center","children":[["$","div",null,{"className":"relative w-full h-64 bg-gray-800","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1718270824.jpeg","alt":"Gordan Sanghera - undefined","fill":true,"className":"object-cover","sizes":"(max-width: 768px) 100vw, (max-width: 1200px) 50vw, 33vw"}]}],["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h3",null,{"className":"text-xl font-semibold text-white mb-1","children":"Gordan Sanghera"}],["$","p",null,{"className":"text-blue-400 font-medium","children":"$undefined"}]]}],"$undefined",["$","footer",null,{"children":["$","a",null,{"href":"https://www.linkedin.com/in/gordon-sanghera-2430861/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View Gordan Sanghera's LinkedIn profile - opens in new tab","children":[["$","svg",null,{"className":"w-4 h-4 mr-2","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}],"LinkedIn Profile"]}]}]]}]]}],["$","article","3638",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200 text-center","children":[["$","div",null,{"className":"relative w-full h-64 bg-gray-800","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1718270883.jpeg","alt":"Nick Keher - undefined","fill":true,"className":"object-cover","sizes":"(max-width: 768px) 100vw, (max-width: 1200px) 50vw, 33vw"}]}],["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h3",null,{"className":"text-xl font-semibold text-white mb-1","children":"Nick Keher"}],["$","p",null,{"className":"text-blue-400 font-medium","children":"$undefined"}]]}],"$undefined",["$","footer",null,{"children":["$","a",null,{"href":"https://www.linkedin.com/in/nicholas-keher-22009322/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View Nick Keher's LinkedIn profile - opens in new tab","children":[["$","svg",null,{"className":"w-4 h-4 mr-2","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}],"LinkedIn Profile"]}]}]]}]]}],["$","article","3639",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200 text-center","children":[["$","div",null,{"className":"relative w-full h-64 bg-gray-800","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1718270947.jpeg","alt":"Dr Spike Willcocks - undefined","fill":true,"className":"object-cover","sizes":"(max-width: 768px) 100vw, (max-width: 1200px) 50vw, 33vw"}]}],["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h3",null,{"className":"text-xl font-semibold text-white mb-1","children":"Dr Spike Willcocks"}],["$","p",null,{"className":"text-blue-400 font-medium","children":"$undefined"}]]}],"$undefined",["$","footer",null,{"children":["$","a",null,{"href":"https://www.linkedin.com/in/spike-willcocks-88319b32/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View Dr Spike Willcocks's LinkedIn profile - opens in new tab","children":[["$","svg",null,{"className":"w-4 h-4 mr-2","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}],"LinkedIn Profile"]}]}]]}]]}]]}]]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative md:max-w-[800px] mx-auto my-8 md:!px-0","children":[["$","div",null,{"id":"faq","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"aria-label":"Frequently Asked Questions","children":[["$","header",null,{"className":"flex flex-col w-full items-center mb-4","children":["$","div",null,{"className":"flex flex-col gap-1 md:gap-4","children":[["$","h2",null,{"className":"text-xl md:text-[36px] max-w-[584px] md:w-full md:text-center font-semibold text-white","children":"What the Pro's Are Asking"}],["$","p",null,{"className":"text-dark-text md:text-center text-base max-w-[584px]","children":"Here are the questions that professional investors are asking before making an investment decision."}]]}]}],["$","div",null,{"className":"space-y-4","children":[["$","details","4511",{"className":"group bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden","children":[["$","summary",null,{"className":"flex items-center justify-between p-4 cursor-pointer hover:bg-[#2A2930] transition-colors duration-200","children":[["$","h3",null,{"className":"text-white font-medium pr-4","children":"What are the key uses?"}],["$","svg",null,{"className":"w-5 h-5 text-gray-400 transform transition-transform duration-200 group-open:rotate-180 flex-shrink-0","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M19 9l-7 7-7-7"}]}]]}],["$","div",null,{"className":"px-4 pb-4","children":["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"Clinical Diagnostics, Infectious Disease Monitoring, Environmental DNA Analysis, Agricultural Research, Microbiome Studies, Genomics Research, Ancient DNA Studies, Forensic Analysis and Space Research."}}]}]]}],["$","details","4512",{"className":"group bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden","children":[["$","summary",null,{"className":"flex items-center justify-between p-4 cursor-pointer hover:bg-[#2A2930] transition-colors duration-200","children":[["$","h3",null,{"className":"text-white font-medium pr-4","children":"How does Oxford Nanopore Technologies contribute to global health and sustainability goals?"}],["$","svg",null,{"className":"w-5 h-5 text-gray-400 transform transition-transform duration-200 group-open:rotate-180 flex-shrink-0","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M19 9l-7 7-7-7"}]}]]}],["$","div",null,{"className":"px-4 pb-4","children":["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"Health and Well-being (SDG 3): ONT's sequencing technology aids in reducing maternal mortality, preventing deaths of children under five, combating epidemics, and reducing deaths from pollution. It supports real-time diagnostics and monitoring of infectious diseases, improving overall healthcare outcomes. Environmental Sustainability: The technology is used for environmental testing, including monitoring water quality and detecting contaminants, which contributes to the goals of clean water and sanitation (SDG 6) and life on land and underwater (SDG 14 and 15). Additionally, ONT's tools help monitor endangered species and support conservation efforts."}}]}]]}],["$","details","4513",{"className":"group bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden","children":[["$","summary",null,{"className":"flex items-center justify-between p-4 cursor-pointer hover:bg-[#2A2930] transition-colors duration-200","children":[["$","h3",null,{"className":"text-white font-medium pr-4","children":"What makes Oxford Nanopore Technologies' sequencing technology unique?"}],["$","svg",null,{"className":"w-5 h-5 text-gray-400 transform transition-transform duration-200 group-open:rotate-180 flex-shrink-0","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M19 9l-7 7-7-7"}]}]]}],["$","div",null,{"className":"px-4 pb-4","children":["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"Oxford Nanopore Technologies (ONT) offers a revolutionary approach to genetic research through its direct nanopore sequencing technology. Unlike traditional sequencing methods, nanopore sequencing can read long stretches of DNA and RNA in real time, providing comprehensive genomic information faster and more accurately. This technology is particularly significant for exploring the \"Dark Genome,\" which is associated with up to 30% of rare diseases. Additionally, ONT’s devices, such as the portable MinION, enable sequencing in various environments, including fieldwork and space, thereby democratising access to advanced genomic analysis."}}]}]]}],["$","details","4514",{"className":"group bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden","children":[["$","summary",null,{"className":"flex items-center justify-between p-4 cursor-pointer hover:bg-[#2A2930] transition-colors duration-200","children":[["$","h3",null,{"className":"text-white font-medium pr-4","children":"How is Oxford Nanopore Technologies positioned to expand its market presence?"}],["$","svg",null,{"className":"w-5 h-5 text-gray-400 transform transition-transform duration-200 group-open:rotate-180 flex-shrink-0","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M19 9l-7 7-7-7"}]}]]}],["$","div",null,{"className":"px-4 pb-4","children":["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"Oxford Nanopore Technologies is strategically expanding its market presence by enhancing its commercial infrastructure and forming key partnerships. The company is increasing its footprint across the Americas, EMEAI (Europe, Middle East, Africa, India), and APAC (Asia-Pacific) regions. Strategic collaborations with organisations such as the Mayo Clinic and bioMérieux are aimed at developing new clinical and industrial applications for their sequencing technology. These efforts are supported by a strong financial position, with substantial cash reserves to sustain operations and investments."}}]}]]}],["$","details","4515",{"className":"group bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden","children":[["$","summary",null,{"className":"flex items-center justify-between p-4 cursor-pointer hover:bg-[#2A2930] transition-colors duration-200","children":[["$","h3",null,{"className":"text-white font-medium pr-4","children":"What are the potential risks to Oxford Nanopore Technologies' growth and market position?"}],["$","svg",null,{"className":"w-5 h-5 text-gray-400 transform transition-transform duration-200 group-open:rotate-180 flex-shrink-0","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M19 9l-7 7-7-7"}]}]]}],["$","div",null,{"className":"px-4 pb-4","children":["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"Financial Challenges: Despite a strong cash reserve, the company has not yet reached breakeven and is not projected to do so until 2027. Continued slower-than-expected sales growth could result in deeper losses and necessitate additional funding.

Commercialization of Long Reads: Transitioning long-read technology from research to practical laboratory applications may take longer than anticipated, potentially delaying commercial success.

Competition: While ONT’s technology is unique, it faces significant competition from established players like Illumina and PacBio. These competitors offer alternative sequencing methods that may be viewed as sufficient for many applications, posing a challenge to ONT’s market share."}}]}]]}]]}]]}]}]]}]]}],["$","$Lb",null,{"id":"financial-product-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"FinancialProduct\",\"name\":\"Oxford Nanopore Technologies\",\"industry\":\"Technology, Healthcare\",\"description\":\"Nvidia, Apple, Oracle and bioMerieux all believe in the story, so why shouldn't you?\",\"url\":\"https://app.curationconnect.com/company/Oxford-Nanopore-Technologies-54181\",\"image\":\"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1741172802.jpeg\",\"identifier\":\"ONT\",\"exchange\":\"LON\",\"price\":118.33,\"priceCurrency\":\"GBX\",\"priceChange\":-2.04,\"marketCap\":1137190051,\"peRatio\":0,\"provider\":{\"@type\":\"Organization\",\"name\":\"Curation Connect\",\"url\":\"https://app.curationconnect.com\"}}"}}],["$","$Lb",null,{"id":"hero-video-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"VideoObject\",\"name\":\"Oxford Nanopore Technologies Overview Video\",\"description\":\"Nvidia, Apple, Oracle and bioMerieux all believe in the story, so why shouldn't you?\",\"thumbnailUrl\":\"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1741172802.jpeg\",\"uploadDate\":\"2025-06-16T18:20:25.553Z\",\"embedUrl\":\"https://www.youtube.com/embed/XphjbhMgcOc?start=undefined\",\"publisher\":{\"@type\":\"Organization\",\"name\":\"Curation Connect\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https://app.curationconnect.com/logo.png\"}}}"}}],["$","$Lb",null,{"id":"ceo-interview-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"VideoObject\",\"name\":\"Oxford Nanopore CEO Interview\",\"description\":\"Interview with the CEO of Oxford Nanopore Technologies\",\"thumbnailUrl\":\"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1741172802.jpeg\",\"uploadDate\":\"2025-06-16T18:20:25.553Z\",\"embedUrl\":\"https://player.vimeo.com/video/957043286?share=copy\",\"publisher\":{\"@type\":\"Organization\",\"name\":\"Curation Connect\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https://app.curationconnect.com/logo.png\"}}}"}}],["$","$Lb",null,{"id":"faq-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$1b"}}],["$","$Lb",null,{"id":"articles-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"ItemList\",\"name\":\"Key Articles\",\"numberOfItems\":1,\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"item\":{\"@type\":\"NewsArticle\",\"headline\":null,\"description\":null,\"url\":\"https://6021764.fs1.hubspotusercontent-na1.net/hubfs/6021764/ONT%20Research%20note%20-%20Curation%20Collective.pdf\",\"author\":{\"@type\":\"Person\",\"name\":\"Unknown\"},\"publisher\":{\"@type\":\"Organization\",\"name\":\"Curation Connect\"}}}]}"}}],["$","$Lb",null,{"id":"team-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$1c"}}],["$","$Lb",null,{"id":"investment-thesis-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$1d"}}],["$","$Lb",null,{"id":"experts-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$1e"}}],["$","$Lb",null,{"id":"investor-materials-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$1f"}}],["$","$Lb",null,{"id":"external-insights-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$20"}}],["$","div",null,{"className":"w-full","children":["$","$L21",null,{"data":{"project_id":null,"showcase_id":1812,"assistant_id":"asst_3ka61sPv1dggnpsZ3w79fwoK","enable_curation_ai":true,"agent_id":null,"intent":null,"title":"Oxford Nanopore Technologies","description":"Oxford Nanopore Technologies (ONT) is a pioneering biotechnology company that is revolutionising genetic research and diagnostics with its innovative nanopore sequencing technology.","type":"text","private_showcase":false,"logo":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1741172802.jpeg","x_link":"https://twitter.com/nanopore","showcase_heading":"Oxford Nanopore: Reading DNA Like Never Before","executive_summary_title":"Decoding tomorrow","executive_summary":"$22","investor_relations_link":"https://app.curationconnect.com/account/signup","investor_relations_label":"+Watchlist","graph_link":"https://jika.io/embed/area-chart?symbol=ONT.L&selection=one_year&closeKey=close&boxShadow=true&graphColor=1652f0&textColor=161c2d&backgroundColor=FFFFFF&fontFamily=Nunito","contact_email":"nirav.karia@curationcorp.com","slug":"Oxford-Nanopore-Technologies-54181","status":"live","usp_cta":null,"usp_cta_link":null,"catalyst_cta":null,"catalyst_cta_link":null,"teaser_video":"https://www.youtube.com/watch?v=XphjbhMgcOc&ab_channel=OxfordNanoporeTechnologies","teaser_video_iframe_url":"https://www.youtube.com/embed/XphjbhMgcOc?start=undefined","teaser_video_label":"Watch Video","teaser_video_title":null,"teaser_video_caption":null,"x_link_label":"Follow Us","hero_caption":"Nvidia, Apple, Oracle and bioMerieux all believe in the story, so why shouldn't you?","hero_cta_label":"+Watchlist","hero_cta_link":"https://app.curationconnect.com/account/signup","hubspot_enabled":false,"disclaimer":null,"discovery_cover_image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1741172830.jpeg","discovery_caption":"Portable DNA/RNA sequencing technology leader","updated_at":"2025-05-02 12:33:10","usps":[{"title":"Market Expansion into Clinical & Biopharma","description":"

","video":null,"video_iframe_url":null},{"title":"Long-read gene sequencing","description":"

","video":null,"video_iframe_url":null},{"title":"Partnerships","description":"

","video":null,"video_iframe_url":null}],"company_contents":[{"theme":"Key Investor Materials","contents":[{"title":"42nd Annual J.P Morgan Healthcare Conference","content":"https://a.storyblok.com/f/196663/x/7ba1f5a928/ont-jpm-final-presentation-9jan2024.pdf","type":"pdf","description":null,"content_iframe_url":null,"showcase_company_content_theme_id":2592},{"title":"hi","content":"https://www.youtube.com/watch?v=nwnGx2i42m8","type":"video","description":"Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.","content_iframe_url":"https://www.youtube.com/embed/nwnGx2i42m8?start=undefined","showcase_company_content_theme_id":2592},{"title":"Single-cell transcriptomics with Oxford Nanopore","content":"https://nanoporetech.com/resource-centre/getting-started-guide-single-cell-transcriptomics","type":"article","description":"This guide introduces the single-cell RNA nanopore sequencing workflow, for ultra-rich data without compromise.","content_iframe_url":null,"showcase_company_content_theme_id":2592},{"title":"2024 Interim Results","content":"https://a.storyblok.com/f/196663/x/f265e0a793/ont-2024-interim-results-presentation-slides-3-sep-2024-final.pdf","type":"pdf","description":null,"content_iframe_url":null,"showcase_company_content_theme_id":2592}]},{"theme":"Gene Sequencing","contents":[{"title":"How sequencing works","content":"https://www.youtube.com/watch?v=E0z4waO35QI","type":"video","description":"Whether you missed it first time, or want to revisit the presentations, this is a great opportunity to watch Oxford Nanopore's lunchtime satellite session fr...","content_iframe_url":"https://www.youtube.com/embed/E0z4waO35QI","showcase_company_content_theme_id":2593},{"title":"Oxford Nanopore announces breakthrough technology performance to deliver complete human genome assemblies and richer multiomic data in London Calling","content":"https://nanoporetech.com/news/oxford-nanopore-announces-breakthrough-technology-performance-to-deliver-complete-human-genomes-and-richer-multiomic-data-in-london-calling-tech-update","type":"article","description":"Oxford Nanopore Chief Technology, Innovation and Product Officer Clive G Brown announced breakthrough performance data and new platform updates in his technology update at the company’s annual London Calling conference, held between 21 and 24 May 2024.","content_iframe_url":null,"showcase_company_content_theme_id":2593},{"title":"Sustainability Report","content":"https://a.storyblok.com/f/196663/x/947e918766/fy_23_sustainability_report-v2.pdf","type":"pdf","description":null,"content_iframe_url":null,"showcase_company_content_theme_id":2593},{"title":"Nanopore sequencing solutions for cell and gene therapies","content":"https://a.storyblok.com/f/196663/78c2e3cc25/biopharma-cgt-brochure-br_1220-en-_v1_15jan2024.pdf","type":"pdf","description":null,"content_iframe_url":null,"showcase_company_content_theme_id":2593}]}],"external_insights":[{"theme":"Partnerships","contents":[{"title":"ONT x Nvidia 1","content":"https://www.youtube.com/watch?v=UNZcwGNYiGY","type":"video","description":"Oxford Nanopore is further accelerating its research with Cambridge-1, enabling its algorithms team to achieve same day results that accelerate research with...","content_iframe_url":"https://www.youtube.com/embed/UNZcwGNYiGY","showcase_external_insight_theme_id":2519},{"title":"ONT x Nvidia 2","content":"https://www.youtube.com/watch?v=dnKJTaYoAh8","type":"video","description":"In January 2022, the New England Journal of Medicine published a record-breaking technique where a whole genome was sequenced in 7 hours and 18 minutes. This...","content_iframe_url":"https://www.youtube.com/embed/dnKJTaYoAh8","showcase_external_insight_theme_id":2519},{"title":"Mayo Clinic and Oxford Nanopore announce collaboration to advance precision medicine for cancer and genetic disorders","content":"https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-and-oxford-nanopore-announce-collaboration-to-advance-precision-medicine-for-cancer-and-genetic-disorders/","type":"article","description":null,"content_iframe_url":null,"showcase_external_insight_theme_id":2519},{"title":"Gordon Sanghera, Co-Founder and CEO","content":"https://open.spotify.com/embed/episode/2AlvvggQsgAdskpiacdqSO?si=aVE9eHhfScSnohKztIugJA","type":"podcast","description":"In January 2022, the New England Journal of Medicine published a record-breaking technique where a whole genome was sequenced in 7 hours and 18 minutes. This...","content_iframe_url":"https://www.youtube.com/embed/dnKJTaYoAh8","showcase_external_insight_theme_id":2519}]},{"theme":"Academic Research","contents":[{"title":"MinIOn","content":"https://www.youtube.com/watch?v=FZeqKRtfKFU","type":"video","description":"Flongle, GridION, MinION, MinIT, PromethION, and VolTRAX are currently for research use only.","content_iframe_url":"https://www.youtube.com/embed/FZeqKRtfKFU","showcase_external_insight_theme_id":2520},{"title":"Cancer Genomics Consortium","content":"https://www.youtube.com/watch?v=4iqTVa5-ePQ","type":"video","description":"Oxford Nanopore Technologies - 2021 CGC Virtual Annual Meeting. The Cancer Genomics Consortium (CGC - https://cancergenomics.org/) represents a dedicated gro...","content_iframe_url":"https://www.youtube.com/embed/4iqTVa5-ePQ","showcase_external_insight_theme_id":2520},{"title":"Oxford Nanopore Technologies: a revolution in DNA and RNA sequencing technology","content":"https://www.mpls.ox.ac.uk/research/impact-case-studies/oxford-nanopore-technologies","type":"article","description":"Only 20 years ago DNA sequencing was expensive, time-consuming and required specialised lab equipment. Oxford Nanopore Technologies’ low-cost, fast, portable, nanopore-based direct sequencing technology is opening up a wide range of new applications that would not have been possible in the early 2000s.","content_iframe_url":null,"showcase_external_insight_theme_id":2520},{"title":"Long read sequencing","content":"https://open.spotify.com/embed/episode/1H7SOKRg4DTbDxUXQB7e1f?si=fI3_sBK8TwGEKATDeC3dfg","type":"podcast","description":null,"content_iframe_url":null,"showcase_external_insight_theme_id":2520}]},{"theme":"Use Cases","contents":[{"title":"LSE webinar","content":"https://www.youtube.com/watch?v=J9IdgL0lMOg","type":"video","description":"LSEG’s Marcus Stuttard speaks to Dr Gordon Sanghera, CEO and Co-Founder of Oxford Nanopore Technologies, about the UK-based biotech company’s route to market...","content_iframe_url":"https://www.youtube.com/embed/J9IdgL0lMOg","showcase_external_insight_theme_id":2521},{"title":"World's smallest gene sequencer","content":"https://www.youtube.com/watch?v=-pwXXzu17JQ","type":"video","description":"Sissel joined Oxford Nanopore 10 years ago and leads the multidisciplinary Applications teams globally. These teams aim to demonstrate and extend the utility...","content_iframe_url":"https://www.youtube.com/embed/-pwXXzu17JQ","showcase_external_insight_theme_id":2521},{"title":"Nanopore sequencing technology, Bioinformatics and applications","content":"https://www.nature.com/articles/s41587-021-01108-x","type":"article","description":"Au and colleagues outline the field of nanopore sequencing.","content_iframe_url":null,"showcase_external_insight_theme_id":2521},{"title":"ONT and Gordon Sanghera","content":"https://open.spotify.com/embed/episode/2LfpMGldVuJEj2gWXe1Zlf?si=r96JPM9aSDuqjADT2RPgyQ","type":"podcast","description":null,"content_iframe_url":null,"showcase_external_insight_theme_id":2521}]}],"experts":[{"id":3727,"name":"Andrew Gao","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1722953638.jpeg","expertise":"Science and venture commentator","audience":"35.8k","x_link":"https://x.com/itsandrewgao","linkedin":"https://www.linkedin.com/in/andrewgao22/","website":"https://andrewgao.dev/","quotes":[{"id":5162,"showcase_expert_id":3727,"platform":"x","type":"text","content":"“It cost $3billion to sequence the first human genome… Oxford Nanopore is developing a tiny DNA sequencer that plugs into your iPhone, and might cost ~$1,000”","cta_label":"See more","cta_link":"https://x.com/itsandrewgao/status/1794488206995636230","title":null}]},{"id":3728,"name":"Greg Smith","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1722956500.jpeg","expertise":"CEO at IP Group","audience":"1k","x_link":"https://x.com/FierceBiotech","linkedin":"https://www.linkedin.com/in/greg-smith-5a99b9/","website":"https://www.fiercebiotech.com/","quotes":[{"id":5163,"showcase_expert_id":3728,"platform":"linkedin","type":"text","content":"“[Long read gene sequencing has] the power to change lives, reducing what can be a lifetime of genetic tests to weeks or days with the richer data that ONT enables.”","cta_label":"See more","cta_link":"https://www.linkedin.com/feed/update/urn:li:activity:7201191054258110464/","title":null},{"id":5164,"showcase_expert_id":3728,"platform":"linkedin","type":"text","content":"“Gordon Sanghera, set out the many commercial partnerships through which ONT is seeking to unlock high potential applied sequencing markets.”","cta_label":"See more","cta_link":"https://www.linkedin.com/feed/update/urn:li:activity:7201191054258110464/","title":null},{"id":5165,"showcase_expert_id":3728,"platform":"linkedin","type":"text","content":"“Longer term, the real prize is in the ‘applied markets’ so it was great to see an overview of the pathway for their products through to future, regulated in-vitro diagnostics.”","cta_label":"See more","cta_link":"https://www.linkedin.com/feed/update/urn:li:activity:7201191054258110464/","title":null},{"id":5166,"showcase_expert_id":3728,"platform":"linkedin","type":"text","content":"“[Infectious disease] is an area where nanopore-based sequencing is mature as well as giving the market advantages of speed and suitability for any setting.”","cta_label":"See more","cta_link":"https://www.linkedin.com/feed/update/urn:li:activity:7201191054258110464/","title":null}]},{"id":3729,"name":"Dr Rebecca Tarvin","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1740665242.jpeg","expertise":"Assistant Professor at University of California, Berkeley","audience":"5k","x_link":"https://x.com/frogsicles","linkedin":"https://www.linkedin.com/in/rebecca-tarvin-0b9a801b/","website":"https://ib.berkeley.edu/people/faculty/tarvinr","quotes":[{"id":5167,"showcase_expert_id":3729,"platform":"x","type":"text","content":"\"In particular, the cost to sequence ...1kb...with Sanger sequencing abroad is ∼$20 USD. In contrast, the cost to sequence a gene with an Oxford Nanopore Technologies instrument locally is only ∼$1.73 USD.\" awesome impact”","cta_label":"Read Here","cta_link":"https://x.com/frogsicles/status/1891994451394036127","title":null}]},{"id":3730,"name":"Aponia Analytics","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1740666043.jpeg","expertise":"global health intelligence","audience":"4k","x_link":"https://x.com/AponiaAnalytics","linkedin":"https://www.linkedin.com/company/aponia-analytics/posts/?feedView=all","website":"https://aponiaholding.com/","quotes":[{"id":5168,"showcase_expert_id":3730,"platform":"x","type":"text","content":"“Oxford Nanopore’s sequencing will improve disease detection in cancer, rare diseases, and infections.”","cta_label":"Read Here","cta_link":"https://x.com/AponiaAnalytics/status/1889371261320548798","title":null}]}],"catalysts":[{"id":3976,"showcase_id":1812,"type":"short","description":"

Drug-Resistant TB Profiling Partnership with bioMérieux

Expansion into Biopharma Markets

","cta_name":null,"cta_link":null,"video":null,"video_iframe_url":null},{"id":3977,"showcase_id":1812,"type":"medium","description":"

Progress Towards Cash Flow Positive

Cutting-Edge Technology & Innovation Pipeline

ONT is advancing into protein sequencing, potentially unlocking a new multi-billion-dollar market in the coming years.

","cta_name":null,"cta_link":null,"video":null,"video_iframe_url":null},{"id":3978,"showcase_id":1812,"type":"long","description":"$23","cta_name":null,"cta_link":null,"video":null,"video_iframe_url":null}],"ceo_interviews":[{"id":2016,"showcase_id":1812,"title":"Oxford Nanopore CEO Interview","video":"https://vimeo.com/957043286?share=copy","video_iframe_url":"https://player.vimeo.com/video/957043286?share=copy","cover_image":null}],"faqs":[{"id":4511,"showcase_id":1812,"question":"What are the key uses?","answer":"Clinical Diagnostics, Infectious Disease Monitoring, Environmental DNA Analysis, Agricultural Research, Microbiome Studies, Genomics Research, Ancient DNA Studies, Forensic Analysis and Space Research.","video":null,"video_iframe_url":null},{"id":4512,"showcase_id":1812,"question":"How does Oxford Nanopore Technologies contribute to global health and sustainability goals?","answer":"Health and Well-being (SDG 3): ONT's sequencing technology aids in reducing maternal mortality, preventing deaths of children under five, combating epidemics, and reducing deaths from pollution. It supports real-time diagnostics and monitoring of infectious diseases, improving overall healthcare outcomes. Environmental Sustainability: The technology is used for environmental testing, including monitoring water quality and detecting contaminants, which contributes to the goals of clean water and sanitation (SDG 6) and life on land and underwater (SDG 14 and 15). Additionally, ONT's tools help monitor endangered species and support conservation efforts.","video":null,"video_iframe_url":null},{"id":4513,"showcase_id":1812,"question":"What makes Oxford Nanopore Technologies' sequencing technology unique?","answer":"Oxford Nanopore Technologies (ONT) offers a revolutionary approach to genetic research through its direct nanopore sequencing technology. Unlike traditional sequencing methods, nanopore sequencing can read long stretches of DNA and RNA in real time, providing comprehensive genomic information faster and more accurately. This technology is particularly significant for exploring the \"Dark Genome,\" which is associated with up to 30% of rare diseases. Additionally, ONT’s devices, such as the portable MinION, enable sequencing in various environments, including fieldwork and space, thereby democratising access to advanced genomic analysis.","video":null,"video_iframe_url":null},{"id":4514,"showcase_id":1812,"question":"How is Oxford Nanopore Technologies positioned to expand its market presence?","answer":"Oxford Nanopore Technologies is strategically expanding its market presence by enhancing its commercial infrastructure and forming key partnerships. The company is increasing its footprint across the Americas, EMEAI (Europe, Middle East, Africa, India), and APAC (Asia-Pacific) regions. Strategic collaborations with organisations such as the Mayo Clinic and bioMérieux are aimed at developing new clinical and industrial applications for their sequencing technology. These efforts are supported by a strong financial position, with substantial cash reserves to sustain operations and investments.","video":null,"video_iframe_url":null},{"id":4515,"showcase_id":1812,"question":"What are the potential risks to Oxford Nanopore Technologies' growth and market position?","answer":"Financial Challenges: Despite a strong cash reserve, the company has not yet reached breakeven and is not projected to do so until 2027. Continued slower-than-expected sales growth could result in deeper losses and necessitate additional funding.\n\nCommercialization of Long Reads: Transitioning long-read technology from research to practical laboratory applications may take longer than anticipated, potentially delaying commercial success.\n\nCompetition: While ONT’s technology is unique, it faces significant competition from established players like Illumina and PacBio. These competitors offer alternative sequencing methods that may be viewed as sufficient for many applications, posing a challenge to ONT’s market share.","video":null,"video_iframe_url":null}],"researches":[],"articles":[{"id":2733,"showcase_id":1812,"title":null,"description":null,"link":"https://6021764.fs1.hubspotusercontent-na1.net/hubfs/6021764/ONT%20Research%20note%20-%20Curation%20Collective.pdf","date":null}],"team_members":[{"id":3636,"showcase_id":1812,"name":"Clive Brown","role":"Chief Technology, Innovation and Product Officer","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1718270988.jpeg","linkedin":"https://www.linkedin.com/in/clive-brown-58507a178/","x_link":null,"description":"Clive leads the innovation of breakthrough technologies and product development, that are designed to enable the analysis of anything, by anyone, anywhere. Clive has held a variety of roles in Genomics and Genetic R&D, he has also played a key role in developing the Solexa NGS platform that is now the basis for Illumina's sequencing technology"},{"id":3637,"showcase_id":1812,"name":"Gordan Sanghera","role":"Chief Executive Officer","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1718270824.jpeg","linkedin":"https://www.linkedin.com/in/gordon-sanghera-2430861/","x_link":"https://x.com/gordon_sanghera","description":"Gordon Sanghera is a Co-Founder of Oxford Nanopore. He was appointed CEO in May 2005 and has led the company through multiple finance rounds, and in 2021, a listing on the London Stock Exchange. Dr Sanghera’s PhD in bioelectronic technology was followed by a career at MediSense where he held positions including VP World Wide Marketing, Research Director and Manufacturing Process Development Director."},{"id":3638,"showcase_id":1812,"name":"Nick Keher","role":"Chief Financial Officer","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1718270883.jpeg","linkedin":"https://www.linkedin.com/in/nicholas-keher-22009322/","x_link":"https://x.com/nanopore","description":"Nick is an experienced life sciences CFO, having previously served as CFO of Clinigen Group and Benevolent AI. Before his CFO roles, he gained extensive experience in the life sciences industry serving as Managing Director and Head of the European healthcare equity research team at Royal Bank of Canada (RBC) before that held roles at Investec and GSK after switching from practising pharmacy"},{"id":3639,"showcase_id":1812,"name":"Dr Spike Willcocks","role":"Chief Strategy Officer","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1718270947.jpeg","linkedin":"https://www.linkedin.com/in/spike-willcocks-88319b32/","x_link":"https://x.com/Spikew3","description":"Spike joined Oxford Nanopore at the start of 2006, leading the Corporate and Business development function, and now is the company's Chief Strategy Officer. He studied at The University of Oxford and completed a Dphil in Biochemistry, after this he worked for the intellectual property investment business \"IP Group\" in 2001 as an early employee"}],"showcase_stocks":{"id":1702,"showcase_id":1812,"exchange":"LON","symbol":"ONT","price":118.33,"change_percent":-2.04,"average_volume":2570459,"marketcap":1137190051,"pe_ratio":0,"raise_amount":null,"equity_offered":null,"valuation":null,"revenue":null,"market_opportunity":null,"raise_amount_currency":null,"valuation_currency":null,"revenue_currency":null,"market_opportunity_currency":null,"target_price":null,"price_target_disclaimer":null},"stock_symbol":"LSE:ONT","exchange":"LON","symbol":"ONT","price":118.33,"change_percent":-2.04,"average_volume":2570459,"marketcap":1137190051,"pe_ratio":0,"raise_amount":null,"equity_offered":null,"valuation":null,"revenue":null,"market_opportunity":null,"raise_amount_currency":null,"valuation_currency":null,"revenue_currency":null,"market_opportunity_currency":null,"target_price":null,"price_target_disclaimer":null,"target_price_change_percentage":null,"buy":[{"id":2147,"showcase_id":1812,"type":"buy","title":"Expanding Clinical & Biopharma Adoption","caption":"ONT is rapidly growing in clinical genomics, with large-scale contracts supporting long-term revenue expansion."},{"id":2148,"showcase_id":1812,"type":"buy","title":"Technology Leadership","caption":"Oxford Nanopore is the only company globally producing handheld, portable sequencing devices for real-time, in-field DNA/RNA analysis, —that sets it apart in next-generation genomic analysis."},{"id":2149,"showcase_id":1812,"type":"buy","title":"Broad Global Applicability","caption":"ONT devices are deployed across multiple sectors spanning healthcare, agriculture, environmental science, and academic research, enhancing ONT’s market resilience and expanding its TAM."}],"sell":[{"id":2150,"showcase_id":1812,"type":"sell","title":"Competition from Established Players","caption":"Illumina and PacBio remain formidable competitors, leveraging existing market share and technology advancements."},{"id":2151,"showcase_id":1812,"type":"sell","title":"Profitability Concerns","caption":"ONT has yet to achieve consistent profitability, with high R&D and expansion costs potentially delaying EBITDA breakeven."},{"id":2152,"showcase_id":1812,"type":"sell","title":"Execution Risk in Clinical Expansion","caption":"The transition from research to clinical applications presents regulatory and adoption challenges that may slow market penetration."}],"key_risks":[{"id":915,"showcase_id":1812,"title":"Competitive Pressures","description":"

","video":"https://google.com","video_iframe_url":null},{"id":916,"showcase_id":1812,"title":"Profitability & Cash Flow Management","description":"

","video":"https://google.com","video_iframe_url":null},{"id":917,"showcase_id":1812,"title":"Regulatory & Market Adoption Challenges","description":"

","video":"https://google.com","video_iframe_url":null}],"industries":[{"id":76,"industry_id":10,"name":"Technology"},{"id":77,"industry_id":6,"name":"Healthcare"}],"tag":{"id":108,"showcase_id":1812,"company_size":"medium","region":"uk","type_of_stock":"gowth","revenue_stage":"post_revenue","mag7":false,"buy_back":false,"income":false,"debt":false,"management_ownership_more_than_5_percent":true},"prompts":[{"id":127,"showcase_id":1812,"sequence":1,"question":"What are the company's revenues?"},{"id":128,"showcase_id":1812,"sequence":2,"question":"Is the company profitable?"},{"id":129,"showcase_id":1812,"sequence":3,"question":"How much cash does it have?"},{"id":130,"showcase_id":1812,"sequence":4,"question":"Who are the top 5 biggest shareholders?"},{"id":131,"showcase_id":1812,"sequence":5,"question":"Tell me about the CEO's background"},{"id":132,"showcase_id":1812,"sequence":6,"question":"Who are the major competitors?"},{"id":133,"showcase_id":1812,"sequence":7,"question":"What is the market opportunity?"}]},"slug":"Oxford-Nanopore-Technologies-54181"}]}]]}]